Vivax Malaria Clinical Trial
Official title:
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
The study will be an open-labelled randomized clinical trial to determine therapeutic efficacy. Note that this will not be an Investigational New Drug application, as only World Health Organization (WHO)-approved drugs will be used at dosage and for conditions approved.
The study will be an open-labelled randomized clinical trial to determine therapeutic efficacy. Note that this will not be an Investigational New Drug application, as only World Health Organization-approved drugs will be used at dosage and for conditions approved. Eligible patients willing to participate will first be tested prior to enrolment for their glucose-6-phosphate dehydrogenase (G6PD) status by the gold standard spectrophotometric analysis. The investigators will exclude from the study any G6PD deficient (or intermediate females) patient. Treatment allocation will be randomized between i) 7 days of artesunate (2 mg/kg/day for 7 days) alone (Arm1), ii) same artesunate regimen + 0.25 mg/kg/day 14 days of primaquine (Arm2) and iii) same artesunate regimen + 0.5 mg/kg/day 14 days of primaquine (Arm3). All patients will be relocated to a no-transmission city to make sure they are not reinfected during the follow-up. Follow-up will be performed every 24-48h for 90 days. At the end of the follow-up period, all patients that did not receive primaquine (arm1) will be treated according to national guidelines (14 days at 0.25mg/kg/day). Patients will additionally be followed monthly for three months after the end of the relocation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01625871 -
Artemether/Lumefantrine and Vivax Malaria
|
Phase 3 | |
| Completed |
NCT02876549 -
G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria
|
Phase 4 | |
| Completed |
NCT01218932 -
Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04228315 -
Biomarkers of P. Vivax Relapse
|
N/A | |
| Completed |
NCT02118090 -
Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:
|
Phase 4 | |
| Completed |
NCT01074905 -
Study on the Treatment of Vivax Malaria
|
Phase 3 | |
| Completed |
NCT04222088 -
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
|
||
| Completed |
NCT01546961 -
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
|
N/A | |
| Completed |
NCT00158548 -
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
|
Phase 3 | |
| Completed |
NCT00682578 -
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
|
Phase 3 | |
| Completed |
NCT00157833 -
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
|
N/A | |
| Active, not recruiting |
NCT03529396 -
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
|
Phase 2 | |
| Recruiting |
NCT05874271 -
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
|
N/A | |
| Completed |
NCT05958797 -
TES of Chloroquine for Pv in the Philippines in 2016
|
||
| Completed |
NCT01716260 -
Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
|
N/A | |
| Completed |
NCT01288820 -
Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria
|
Phase 3 | |
| Completed |
NCT01640574 -
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
|
Phase 3 | |
| Completed |
NCT01076868 -
Incidence of Vivax Along the Thai Burma Border
|
N/A | |
| Completed |
NCT00158561 -
Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria
|
Phase 3 | |
| Completed |
NCT01780753 -
Primaquine Pharmacokinetics in Lactating Women and Their Infants
|
Phase 1 |